First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study

Aranda, E; Garcia-Alfonso, P; Benavides, M; Ruiz, AS; Guillen-Ponce, C; Safont, MJ; Alcaide, J; Gomez, A; Lopez, R; Manzano, JL; Urena, MM; Sastre, J; Rivera, F; Gravalos, C; Garcia, T; Martin-Valades, JI; Falco, E; Navalon, M; Flores, EG; Tapiador,

Aranda, E (reprint author), Hosp Reina Sofia, C Menendez Pidal S-N, Cordoba 14004, Spain.

EUROPEAN JOURNAL OF CANCER, 2018; 101 (): 263

Abstract

Background: This multicentre, randomised, and phase II study evaluated mFOL-FOX+cetuximab followed by maintenance mFOLFOX+cetuximab or single-agent ce......

Full Text Link